About BONESUPPORT

News/Press Releases German
 

BONESUPPORT AB ANNOUNCES CHUV IN SWITZERLAND INITIATES STUDY OF CERAMENT™|G FOR ONE-STAGE SURGICAL REVISION OF BONE INFECTIONS

19th June 2014

 

Lund, Sweden, (PRNEWSWIRE) June 19, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced the initiation of a CERAMENT™|G Bone Healing study by the CHUV (Centre Hospitalier Universitaire Vaudois), in Lausanne, Switzerland. The CERAMENT™|G Bone Healing study is a prospective, controlled, cohort study investigating the absorption and bone in-growth of CERAMENT™|G in one-stage surgical revisions of bone infections. Dr. Olivier Borens, head of the septic unit at the CHUV, is principal clinical investigator for the study, which will follow patients for 12 months post surgery.

NEW CERAMENT™ APP AVAILABLE ON APP STORE - Features clinical indications for CERAMENT™|BONE VOID FILLER

30th April 2014

 

Lund, Sweden,(PRNEWSWIRE) April 30, 2014 – BONESUPPORT,an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced the release of a new iPad® app called, CERAMENT™, now available for download from iTunes®. The CERAMENT™ app is designed to impart valuable information on the indications and clinical experience with CERAMENT™|BONE VOID FILLER. The app runs off the cloud, allowing for real-time, seamless updates of new clinical experiences, case studies, and other pertinent information.

FIRST CERAMENT™|G STUDY WITH LOCAL GENTAMICIN ELUTION SHOWS SAFE BONE HEALING WITH EFFECTIVE NEW BONE INGROWTH IN OSTEOMYELITIS PATIENTS

15th April 2014

 

Lund, Sweden, (PRNEWSWIRE) April 15, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced the first patient outcomes data of CERAMENT™|G pertaining to an ongoing clinical trail in patients with osteomyelitis, as presented at The 4th Annual Oxford Bone Infection Conference. In the report, forty-one patients treated with CERAMENT™|G had no recurrence of infection, no late wound leakage, no toxicity and no renal complications at a mean follow-up of 9 months. Additionally, 78% of the patients demonstrated complete bone remodeling at 6 months.

CERTiFy (CERAMENT™|TIBIA FRACTURE) STUDY PROTOCOL PUBLISHED IN TRIALS

12th March 2014

 

Lund, Sweden, (PRNEWSWIRE) March 12, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, together with the University of Mainz in Germany, announced that the protocol for the CERAMENT™|Tibia Fracture Study (CERTiFy) was recently published in TRIALS, an open access, peer reviewed online journal. CERTiFy is a controlled, prospective, randomized clinical trial comparing the use of CERAMENT™|BONE VOID FILLER with the current gold standard for bone graft procedures in the management of tibia plateau fractures. CERTiFy will include 136 patients from more than a dozen top orthopedic trauma centers in Germany.